Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Esomeprazole for the treatment of GERD in infants ages 1-11 months.

Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M.

J Pediatr Gastroenterol Nutr. 2012 Jul;55(1):14-20. doi: 10.1097/MPG.0b013e3182496b35.

PMID:
22241513
2.

Esomeprazole for the Treatment of GERD in Infants Ages 1-11 Months.

Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M.

J Pediatr Gastroenterol Nutr. 2015 Jul;60 Suppl 1:S9-15. doi: 10.1097/MPG.0b013e3182496b35.

PMID:
26422097
3.

Esomeprazole for the Treatment of GERD in Infants Ages 1-11 Months.

Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M.

J Pediatr Gastroenterol Nutr. 2015 Jul;60 Suppl 1:S9-15. doi: 10.1097/MPG.0b013e3182496b35.

PMID:
26121349
4.

Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.

Davidson G, Wenzl TG, Thomson M, Omari T, Barker P, Lundborg P, Illueca M.

J Pediatr. 2013 Sep;163(3):692-8.e1-2. doi: 10.1016/j.jpeds.2013.05.007. Epub 2013 Jun 22.

PMID:
23800403
5.

Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease.

Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M.

J Pediatr Gastroenterol Nutr. 2008 May;46(5):524-33. doi: 10.1097/MPG.0b013e318176b2cb.

PMID:
18493207
6.

Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD.

Winter H, Kum-Nji P, Mahomedy SH, Kierkus J, Hinz M, Li H, Maguire MK, Comer GM.

J Pediatr Gastroenterol Nutr. 2010 Jun;50(6):609-18. doi: 10.1097/MPG.0b013e3181c2bf41.

PMID:
20400912
7.

Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.

Sandström M, Davidson G, Tolia V, Sullivan JE, Långström G, Lundborg P, Brown K.

Clin Ther. 2012 Aug;34(8):1828-38. doi: 10.1016/j.clinthera.2012.06.028. Epub 2012 Jul 24.

PMID:
22832034
8.

Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.

Gold BD, Gunasekaran T, Tolia V, Wetzler G, Conter H, Traxler B, Illueca M.

J Pediatr Gastroenterol Nutr. 2007 Nov;45(5):520-9.

PMID:
18030228
9.

Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.

Tolia V, Gilger MA, Barker PN, Illueca M.

J Pediatr Gastroenterol Nutr. 2010 Nov;51(5):593-8. doi: 10.1097/MPG.0b013e3181ddcf11.

PMID:
20706150
10.
11.

Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.

Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M.

J Pediatr. 2009 Apr;154(4):514-520.e4. doi: 10.1016/j.jpeds.2008.09.054. Epub 2008 Dec 3.

PMID:
19054529
12.

Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers.

Franke A, Hepp C, Harder H, Beglinger C, Singer MV.

Scand J Gastroenterol. 2008;43(12):1425-31. doi: 10.1080/00365520802105110.

PMID:
18924018
13.

Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.

Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M.

J Pediatr Gastroenterol Nutr. 2015 Jul;60 Suppl 1:S16-23. doi: 10.1097/MPG.0b013e318176b2cb.

PMID:
26422093
14.

Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.

Higginbotham TW.

Ann Pharmacother. 2010 Mar;44(3):572-6. doi: 10.1345/aph.1M519. Epub 2010 Feb 2. Review.

PMID:
20124466
15.

Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.

Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M.

J Pediatr Gastroenterol Nutr. 2015 Jul;60 Suppl 1:S16-23. doi: 10.1097/MPG.0b013e318176b2cb.

PMID:
26121345
16.

Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.

Johnson DA, Orr WC, Crawley JA, Traxler B, McCullough J, Brown KA, Roth T.

Am J Gastroenterol. 2005 Sep;100(9):1914-22.

PMID:
16128933
17.

Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease.

Omari T, Davidson G, Bondarov P, Nauclér E, Nilsson C, Lundborg P.

J Pediatr Gastroenterol Nutr. 2007 Nov;45(5):530-7.

PMID:
18030229
18.

The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial.

Moayyedi P, Armstrong D, Hunt RH, Lei Y, Bukoski M, White RJ.

Am J Gastroenterol. 2010 Nov;105(11):2341-6. doi: 10.1038/ajg.2010.368. Epub 2010 Sep 14.

PMID:
20842110
19.

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.

Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T, Omland TM, Delle M, Junghard O.

Aliment Pharmacol Ther. 2001 Mar;15(3):347-54.

20.

Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.

Hussain S, Kierkus J, Hu P, Hoffman D, Lekich R, Sloan S, Treem W.

J Pediatr Gastroenterol Nutr. 2014 Feb;58(2):226-36. doi: 10.1097/MPG.0000000000000195.

PMID:
24121146

Supplemental Content

Support Center